Publication in PLoS Medicine reveals groundbreaking clinical research on broad potential of novel high-density microarray patch (HD-MAP) to efficiently deliver vaccines directly to the skin, enhancing ...
The clinical study aims to evaluate a vaccine for avian influenza A (H7N9) delivered by Vaxxas’ high-density microarray patch (HD-MAP), and is funded by the United States government as a potential ...
Recently published data generated by researchers at The University of Queensland and Vaxxas shows effective delivery of a nucleic acid-based COVID-19 vaccine in a preclinical animal study utilizing ...
CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that research demonstrating the ...
Self-administration of vaccines using the Vaxxas high-density microarray patch (HD-MAP) could reduce the need for healthcare workers to administer vaccines, expanding the rate, broadening the scope, ...
The MarketWatch News Department was not involved in the creation of this content. -- Multi-center Phase I clinical study will evaluate the safety and tolerability of a monovalent strain of avian ...
Reviewed by Dr. Tomislav Meštrović, MD, Ph.D. The microarray is a very recent development in the field of biotechnology. Scientists are now able to understand the gene functions of any organism by ...
For final description of microarray experiment results it is necessary to use some statistically robust method. Transcription maps (TM) are used to map results of gene expression analysis into ...
Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback